Partner With the Proven iPSC Experts

Put the Power of iPSC Technology Behind Your Pipeline

By combining top-tier iPSC-derived cells, deep iPSC technology and application expertise, and excellent customer service, Ncardia helps you make more confident decisions and accelerate the development of breakthrough therapies.

Start a Conversation

iPSC Products & Services

By continually innovating with human induced pluripotent stem cells (iPSC) technology and diving deep on its applications, we have established a portfolio of relevant cell models, screening assays and custom iPSC services to support the development of new drug, gene and cell therapies.

iPSC Products

Physiologically relevant and fully functional cell models, manufactured to scale and readily available.

Explore Our iPSC Products

iPSC Services

Human iPSC-based platforms combining physiologically relevant models with robust and scalable assays to help you select the best drug candidates.

Explore iPSC Services

The Latest From Ncardia

New additions to our CNS portfolio

Introducing our new CNS portfolio. Ncardia has launched Ncyte® Excitatory Neurons and Ncyte® GABAergic Neurons, the first two human iPSC-derived cell models in our expanding CNS portfolio. Designed for CNS drug discovery and safety research, they support studies of neuronal signalling, network activity and excitatory/inhibitory balance.

Explore CNS Porfolio

Cardiomyocyte Supply Impact Calculator

Frequent cardiomyocyte lot changes can lead to revalidation work, added costs, and variability across studies. Ncyte® vCardiomyocytes are manufactured in large-scale batches that support years of consistent supply, helping streamline workflows and maintain continuity throughout your program.

Use our interactive calculator to estimate the potential impact on your screening program.

Launch Calculator

IO Safety Panel

Introducing Ncardia’s IO Safety Panel, a human iPSC-based platform designed to evaluate functional toxicity across multiple relevant tissues within a single, integrated workflow. By combining cardiac and multi-tissue safety readouts, it supports earlier, data-driven decisions and reduces translational uncertainty in immuno-oncology development.